Plasmodium falciparum: Immunogenicity of Alum-Adsorbed Clinical-Grade TBV25–28, a Yeast-Secreted Malaria Transmission-Blocking Vaccine Candidate

2001 ◽  
Vol 97 (2) ◽  
pp. 61-69 ◽  
Author(s):  
Mary Margaret G Gozar ◽  
Olga Muratova ◽  
David B Keister ◽  
Charlotte R Kensil ◽  
Virginia L Price ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Malaria Transmission ◽  
Vaccine Candidate ◽  
Clinical Grade ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccine

scholarly journals Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum

2005 ◽  
Vol 73 (11) ◽  
pp. 7375-7380 ◽  
Author(s):  
Takeshi Arakawa ◽  
Ai Komesu ◽  
Hitoshi Otsuki ◽  
Jetsumon Sattabongkot ◽  
Rachanee Udomsangpetch ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Malaria Transmission ◽  
Vaccine Candidate ◽  
Expression Patterns ◽  
Serum Antibody ◽  
Biologically Active ◽  
Mucosal Transmission ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccines ◽  
Transmission Blocking Vaccine

ABSTRACT Malaria transmission-blocking vaccines based on antigens expressed in sexual stages of the parasites are considered one promising strategy for malaria control. To investigate the feasibility of developing noninvasive mucosal transmission-blocking vaccines against Plasmodium falciparum, intranasal immunization experiments with Pichia pastoris-expressed recombinant Pfs25 proteins were conducted. Mice intranasally immunized with the Pfs25 proteins in the presence of a potent mucosal adjuvant cholera toxin induced robust systemic as well as mucosal antibodies. All mouse immunoglobulin G (IgG) subclasses except IgG3 were found in serum at comparable levels, suggesting that the immunization induced mixed Th1 and Th2 responses. Consistent with the expression patterns of the Pfs25 proteins in the parasites, the induced immune sera specifically recognized ookinetes but not gametocytes. In addition, the immune sera recognized Pfs25 proteins with the native conformation but not the denatured forms, indicating that mucosal immunization induced biologically active antibodies capable of recognizing conformational epitopes of native Pfs25 proteins. Feeding Anopheles dirus mosquitoes with a mixture of the mouse immune sera and gametocytemic blood derived from patients infected with P. falciparum resulted in complete interference with oocyst development in mosquito midguts. The observed transmission-blocking activities were strongly correlated with specific serum antibody titers. Our results demonstrated for the first time that a P. falciparum transmission-blocking vaccine candidate is effective against field-isolated parasites and may justify the investigation of noninvasive mucosal vaccination regimens for control of malaria, a prototypical mucosa-unrelated mosquito-borne parasitic disease.

scholarly journals Evaluation of two lead malaria transmission blocking vaccine candidate antibodies in natural parasite-vector combinations

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Anais Bompard ◽  
Dari F. Da ◽  
Rakiswendé S. Yerbanga ◽  
Sumi Biswas ◽  
Melissa Kapulu ◽  
...  
Keyword(s):  
Malaria Transmission ◽  
Vaccine Candidate ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccine

scholarly journals Engineering a Virus-Like Particle as an Antigenic Platform for a Pfs47-Targeted Malaria Transmission-Blocking Vaccine

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Lampouguin Yenkoidiok-Douti ◽  
Adeline E. Williams ◽  
Gaspar E. Canepa ◽  
Alvaro Molina-Cruz ◽  
Carolina Barillas-Mury
Keyword(s):  
Plasmodium Falciparum ◽  
Amino Acid ◽  
Malaria Transmission ◽  
Transmission Blocking ◽  
High Affinity ◽  
Virus Like Particle ◽  
Antibody Titers ◽  
Reducing Activity ◽  
Sexual Stages ◽  
Transmission Blocking Vaccine

AbstractWe recently characterized Pfs47, a protein expressed on the surface of sexual stages and ookinetes of Plasmodium falciparum, as a malaria transmission-blocking vaccine (TBV) target. Mice immunization induced antibodies that conferred strong transmission-reducing activity (TRA) at a concentration of 200 μg/mL. Here, we sought to optimize the Pfs47 vaccine to elicit higher titers of high-affinity antibodies, capable of inducing strong TRA at a lower concentration. We report the development and evaluation of a Pfs47-based virus-like particle (VLP) vaccine generated by conjugating our 58 amino acid Pfs47 antigen to Acinetobacter phage AP205-VLP using the SpyCatcher:SpyTag adaptor system. AP205-Pfs47 complexes (VLP-P47) formed particles of ~22 nm diameter that reacted with polyclonal anti-Pfs47 antibodies, indicating that the antigen was accessible on the surface of the particle. Mice immunized with VLP-P47 followed by a boost with Pfs47 monomer induced significantly higher antibody titers, with higher binding affinity to Pfs47, than mice that received two immunizations with either VLP-P47 (VLP-P47/VLP-P47) or the Pfs47 monomer (P47/P47). Purified IgG from VLP-P47/P47 mice had strong TRA (83–98%) at concentrations as low as 5 μg/mL. These results indicate that conjugating the Pfs47 antigen to AP205-VLP significantly enhanced antigenicity and confirm the potential of Pfs47 as a TBV candidate.

Geographical distribution of a variant epitope of Pfs4845, a Plasmodium falciparum transmission-blocking vaccine candidate

1996 ◽  
Vol 81 (2) ◽  
pp. 253-257 ◽  
Author(s):  
Christopher J Drakeley ◽  
Manoj T Duraisingh ◽  
Marinete Póvoa ◽  
David J Conway ◽  
Geoffrey A.T Targett ◽  
...  
Keyword(s):  
Plasmodium Falciparum ◽  
Geographical Distribution ◽  
Vaccine Candidate ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccine

Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein

2015 ◽  
Vol 112 (7) ◽  
pp. 1297-1305 ◽  
Author(s):  
Veronique Beiss ◽  
Holger Spiegel ◽  
Alexander Boes ◽  
Stephanie Kapelski ◽  
Matthias Scheuermayer ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Malaria Transmission ◽  
Vaccine Candidate ◽  
Transmission Blocking ◽  
Transmission Blocking Vaccine
Sign in / Sign up

Export Citation Format

Share Document